Drugs / Spirulin Platensis
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04727424 | Jan 2021 → Jun 2024 | COVID-19 | Cardresearch | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spirulin Platensis | “Spirulin Platensis 500mg oral tablets Two tablets right after randomization (day 0) followed by 1.000mg (two tablets) BID for the following 10 days.” NCT04727424 ↗ |
| Modality | Other / unclassified | “Algae-derived nutraceuticals, such as spirulina, have been reported to have biological activities that may minimize clinical consequences to COVID-19 infections.” PMID 39232602 ↗ Aug 2024 |
| Route | Oral | “Spirulin Platensis 500mg oral tablets” NCT04727424 ↗ |